BioSpace News Archive

Neogen® Corporation announced the recipients of Supervised Agricultural Experience Grants, funded through the Company’s 2022 partnership agreement with the National FFA Foundation.

Regular non-burning, moderate exposure to sunlight is commonly assumed to cause cumulative skin damage that may result in photoaging causing wrinkles, age spots, and sagging skin, as well as skin cancers such as melanoma, basal cell carcinoma and squamous cell carcinoma.

Gilead Sciences, Inc. announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy® for the treatment of metastatic urothelial cancer.

Alcami Corporation, a leading contract development and manufacturing organization, announced the promotion of Katie Schlipp to President of Laboratory Operations.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced that the company’s management will participate in a fireside chat event during Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Thursday, March 2, 2023, at 11:45 AM Eastern Time.

Advanced Orthopedics and Sports Medicine Institute is the first in Monmouth County, NJ to perform the BEAR® Implant for treatment of anterior cruciate ligament tears, one of the most common knee injuries in the U.S. The BEAR Implant is the first medical advancement to enable the body to heal its own torn ACL.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 in children and adolescents 6 to 17 years of age.

Oryzon Genomics, S.A. reported financial results for the fourth quarter ended December 31, 2022 and provided an update on recent developments.

The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.

Paragon 28, Inc. announced completion of the sale of an additional 975,000 shares of its common stock, pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters in connection with Paragon’s recently completed underwritten public offering of 6,500,000 shares of common stock, at a public offering price of $17.00 per share, before underwriting discounts and commissions.